Bachem Expands Multi-Site Production Capacities
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK, and Switzerland.
The expansion plans respond to the growing demand for peptides and oligonucleotides therapeutics. With the global market for obesity drugs expected to increase by more than 15-fold by 2030, Bachem continues to scale operations in line with rising demand.
Stepping up Large-Scale Peptide Production at Bubendorf
At its Bubendorf site, Bachem is expanding its large-scale operations with a new state-of-the-art production facility known as Building K.
The building incorporates high-capacity production cells for scalable synthesis, advanced energy systems (heating, cooling, water, cold storage, etc.), and a specialized tank farm for large-scale operations.
Increased Capacities at Vista Site
At their Vista site, Bachem has directed funding to increase annual peptide production capacity to nearly one metric ton.
New features will include:
- Large-scale SPPS reactors for efficient peptide synthesis.
- Cleavage equipment train with two filter dryers to enhance throughput.
- Increased tank farm & waste management to support high-volume operations.
- Automated glass washer & new heating/chilling systems for operational efficiency.
Increasing Production for Diagnostic Peptides at UK Site & Plans for New Sisseln Site
Improvements to Bachem’s St Helens site infrastructure have resulted in a doubling of output, with a focus on the development of research chemicals. Separately, a new site at Sisseln is being developed in northwestern Switzerland, with concept designs underway.
